MARKET

IBIO

IBIO

Ibio
AMEX
0.1570
-0.0130
-7.65%
After Hours: 0.1585 +0.0015 +0.96% 19:35 10/06 EDT
OPEN
0.1699
PREV CLOSE
0.1700
HIGH
0.1705
LOW
0.1530
VOLUME
3.07M
TURNOVER
0
52 WEEK HIGH
0.9900
52 WEEK LOW
0.1530
MARKET CAP
34.25M
P/E (TTM)
-1.0282
1D
5D
1M
3M
1Y
5Y
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Benzinga · 09/29 09:09
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 09/28 16:40
iBio is right to move away from COVID-19 vaccine development - Cantor
Cantor Fitzgerald defended iBio (NYSE:IBIO) after the biotech annou...
Seekingalpha · 09/28 16:16
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Benzinga · 09/28 11:17
After-Hours Alert: Why iBio Stock Is Plunging
IBio Inc (AMEX:IBIO) shares are trading lower in Tuesday's after-hours session after the company reported preliminary results and announced a 1-for-25 reverse split. iBio also said it will not proceed with an IND submission for its COVID-19 vaccine candidate.
Benzinga · 09/27 20:34
BRIEF-Ibio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results
BRIEF-Ibio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results
Reuters · 09/27 20:25
iBio reports FY results
iBio press release (<span class="ticker-hover...
Seekingalpha · 09/27 20:16
iBio Reports FY22 Prelim. Sales Of $2.4M, Up 1% YoY
Preliminary Unaudited Financial Results: Revenues for the fiscal year ended June 30, 2022, were approximately $2.4 million, an increase of 1% over fiscal 2021. R&amp;D and G&amp;A expenses for fiscal 2022 increased
Benzinga · 09/27 20:12
More
About IBIO
iBio, Inc. is a developer of biopharmaceuticals and FastPharming Manufacturing System. The Company is applying its technologies to develop product candidates to treat or prevent fibrotic diseases, cancers, and infectious diseases. The Company is using its FastPharming Manufacturing System (FastPharming System) and Glycaneering Services to build a portfolio of biologic drug candidates. The Company is also using the FastPharming System to create proteins for others by contract through the Company’s catalog. The Company operates through two segments: Biopharmaceuticals and Bioprocessing. Its Biopharmaceuticals segment, which includes development and licensing in two business units: therapeutics and vaccines. Its Bioprocessing, which includes services and products for research and further manufacturing uses, collectively known as Research & Bioprocess products (RBP). Its pipeline includes IBIO-100, IBIO-101, IBIO-202 and IBIO-400.

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.